Neurodegeneration

Neurodegenerative disorders are the leading cause of physical and cognitive disability worldwide, affecting approximately 15% of the global population. Neuroinflammation is not only a hallmark of neurodegenerative diseases, but a prominent and active contributor to disease progression. Therefore, therapeutics dampening neuroinflammation hold significant promise for the treatment of several neurodegenerative diseases.

Neurodegenerative diseases are characterised by a state of chronic inflammation of the nervous system, termed neuroinflammation. Neuroinflammation is not simply a consequence of the tissue damage that occurs in neurodegenerative diseases, but a driver of disease progression. The full range of contributing factors and biological mechanisms that drive neuroinflammation is not fully elucidated, which is why there is value in having access to a range of biological models of increasing complexity to support the discovery of novel drugs in this space.

We offer a range of biological models and cutting-edge instrumentation to support drug discovery in neuroinflammation:

Diverse Biological Systems: By utilising human and rodent models of increasing complexity, from cell cultures to 3D systems, we can support your drug discovery efforts.
A Range of Advanced Technologies: such as High-Content Imaging for in-depth phenotypic characterisation.

Our Capabilities:

Inflammatory Polarisation: Evaluating microglial and astrocytic inflammatory responses.
Inflammasome Activation: Assessing activation of the inflammasome, a key component of inflammatory responses.
Microglial Function: Assessing phagocytosis and migration abilities.
Neurotoxicity/Neuroprotection: Determining the impact on neuronal health and function.

These approaches and capabilities collectively contribute to a comprehensive understanding of neuroinflammation and aid in developing potential treatments for neurodegenerative diseases.